公开(公告)号：KR1020100018741A

公开(公告)日：2010-02-18

申请号：KR1020080077386

申请日：2008-08-07

Applicant: 신풍제약주식회사 ,  충남대학교산학협력단

Inventor： 황성주 ,  박희준 ,  이영주 ,  김민수 ,  김정수 ,  김기원 ,  노정열 ,  남대영

IPC: A61K9/08 ,  A61K31/337 ,  A61P35/00

CPC classification number: A61K47/10 ,  A61K9/0019 ,  A61K31/337 ,  A61K47/12 ,  A61K47/14 ,  A61K47/18 ,  A61K47/34 ,  A61K2121/00

Abstract: PURPOSE: An injection composition for anti-cancer which containing docetaxel as an active ingredient is provided ensure bioavailability same as a conventional injection product and low hemolysis. CONSTITUTION: An injection composition contains docetaxel as an active ingredient, glycofurol(tetrahydrofurfuryl alcohol polyethyleneglycolether) or DMA(dimethylaceteamide) as a solubilizing agent, and solutol, acepol, or poroxamer as a surfactant. The weight ratio between solubilizing agent and surfactant is 1:0.5-6. The pH concentration of the injection composition is adjusted at pH 4-6.

Abstract translation: 目的：提供含有多西紫杉醇作为活性成分的抗癌注射用组合物，确保与常规注射产品相同的生物利用度和低溶血性。 构成：注射用组合物含有作为活性成分的多西紫杉醇，作为增溶剂的糖醇（四氢糠醇聚乙二醇醚）或DMA（二甲基乙酰胺），作为表面活性剂的溶剂型，acepol或poroxamer。 增溶剂与表面活性剂的重量比为1:0.5-6。 注射组合物的pH浓度调节至pH 4-6。